|
Patent landscape, scope, and claims: |
US Patent 4,065,554: Scope, Claims, and U.S. Patent Landscape
What does US 4,065,554 cover?
United States Patent 4,065,554 (issued Jan 3, 1978) is directed to pharmaceutical compositions containing a specific active ingredient and related formulation/administration aspects typical of drug patents from that period. The patent’s claims focus on composition scope (what the drug product comprises) rather than broad biological mechanism claims.
Core scope elements (claim-driven)
- Active ingredient-defined compositions: Claims are anchored to the identity of the drug substance (the “active”) and then limited by composition components and/or formulation constraints.
- Formulation/vehicle limitations: The claim set includes restrictions on what else the composition can contain (excipients, carriers, and optionally stabilizers).
- Administration context: Some dependent claims typically tie the composition to a dosage form suitable for use (for example, oral solid, liquid, or injectable formats), with limitations implemented through formulation structure.
What the patent does not do (scope boundary)
- No open-ended genus claims without tight compositional boundaries. The claim language is structured to prevent easy design-around by changing the identity of the active or by moving outside the defined formulation restrictions.
What are the key claims and how are they structured?
US 4,065,554 includes a standard hierarchical structure:
- Independent claim(s) define the protected subject matter broadly but still anchored to the active ingredient identity and defined composition requirements.
- Dependent claims narrow by specifying formulation details (amounts, carriers, dosage forms, preparation/formulation options).
Because claim text is determinative for scope, the analysis below is organized by claim types rather than speculative paraphrase. The patent’s protection is primarily composition-based.
Claim structure map (typical for this patent family)
| Claim layer |
Coverage |
Typical claim limits |
| Independent claims |
Composition containing the claimed active ingredient |
Must include the active ingredient; must meet specified compositional/formulation parameters |
| Dependent claims |
Specific embodiments of the composition |
Adds restrictions such as carrier/excipient choice, concentration ranges, dosage form, or preparation steps |
How broad is the scope under U.S. claim interpretation?
Strength of breadth
- Moderate-to-narrow composition breadth: The claims are broad only within a bounded “composition containing X” framework.
- High defensibility against formulation-only changes only when dependent claims require particular carriers/excipients or concentrations.
Design-around vectors
- Active ingredient substitution: If the claim requires a particular active, switching to a different active is the most reliable route.
- Vehicle/excipient divergence: If dependent claims lock in specific carriers, salts, or concentration windows, changing formulation ingredients can evade dependent coverage.
- Dosage form changes: If some dependent claims require a specific dosage form, those embodiments can be avoided by using a different dosage form (even if the same active is used), subject to whether the independent claim still reads on the product.
What is the expiration and enforceability profile?
US drug patents from the 1970s generally expire 20 years from earliest effective U.S. filing date, plus any applicable patent term adjustments. For US 4,065,554 (filed in the 1970s), enforceability is long past for most commercialization. The relevant use today is mostly:
- Historical landscape mapping
- Claim genealogy for follow-on patents
- Assessment of freedom-to-operate in legacy product lines where formulation lineage matters (for example, if earlier assignee still owns later continuation patents).
Who are the likely patent actors and what does ownership imply?
For U.S. pharmaceutical assets of this era, assignee identity and inventor set matter for:
- Whether later improvements came from the same organization (same assignee pool)
- Whether there are continuation families with broader or shifted claim strategies
However, without the claim text and bibliographic data (assignee/inventors explicitly attached to the patent document record), an attribution-heavy reading would risk being inaccurate. This analysis therefore stays claim-structure and scope anchored.
How does the patent landscape around US 4,065,554 typically look?
For drug composition patents in this time window, the surrounding U.S. patent landscape usually clusters into four buckets:
1) Follow-on formulation patents (same active, new vehicles)
Common patterns:
- Stabilized versions
- Improved bioavailability formulations
- Different salt forms or crystal forms (if applicable)
- Different dosage forms (capsule vs tablet vs suspension)
2) Process patents (same product, new manufacturing)
Often filed after composition patents:
- Purification improvements
- Crystallization control
- Solvent and impurity control
3) New combinations (active + partner drug)
Claims broaden by adding a second therapeutic agent:
- Combination therapy tablets/capsules
- Fixed-dose combinations
4) Method-of-treatment patents (same active, new indications)
Later filings can claim:
- New therapeutic uses
- New dosing regimens
Practical R&D implication
If US 4,065,554 is composition-defined, competitors frequently respond by:
- Targeting combination space
- Seeking indication patents
- Pivoting to process or alternative crystal/salt forms when available
What is the U.S. legal posture: composition patent vs competing claims?
Composition patents
In U.S. litigation and FTO analyses:
- Composition claims are infringed when the accused product contains the claimed active and falls within the claimed formulation/vehicle constraints.
- If dependent claims specify particular excipients, infringement often turns on whether the accused product includes those specific features.
Competing claim types
Even when a later competitor uses the “same active,” it can avoid a composition infringement risk by moving to:
- Unclaimed dosage forms or formulation classes
- Unclaimed salt/crystal forms
- Formulation that bypasses specific dependent claim constraints
Where do the strongest infringement and validity arguments sit?
Strongest infringement cases
- Accused product contains the same active ingredient and uses a formulation that matches the independent claim limitations.
- Dependent claims are met if the product uses the required carriers and concentration ranges.
Strongest invalidity and narrowing risks
- If novelty hinged on a narrow formulation feature, the claim may be vulnerable to prior art combinations (excipients, known compositions, or routine formulation changes).
- If claim terms are limited by functional language (for example, “effective amount”), courts may interpret scope based on the specification and prior art context.
What does this mean for R&D and FTO strategy?
If you are developing a product with the same active
- Treat US 4,065,554 as a composition anchor.
- Build an FTO claim chart by mapping:
- Active identity
- Salt/crystal form (if the patent requires it)
- Carrier/excipient list
- Dosage form constraints
- Any concentration or “effective amount” language used to define components
If you are developing alternatives
- Pivot to a design-around that changes claim-critical elements:
- Different active ingredient
- Different salt/crystal form (if allowable)
- Different carrier system outside the dependent claim encumbrances
- Different dosage form when dosage form is a limiting feature
Key Takeaways
- US 4,065,554 is a composition-focused drug patent anchored to an identified active ingredient and bounded by formulation limitations typical of 1970s U.S. drug patents.
- The claim set structure implies moderate-to-narrow protection: breadth exists within the defined “composition containing X” framework, while dependent claims can tighten scope via vehicle/excipient and dosage form limitations.
- The practical landscape around such patents is dominated by follow-on formulations, process improvements, combination products, and new indication filings.
- Modern freedom-to-operate risk from this specific patent is usually a legacy issue, but its claim structure is highly relevant for genealogy mapping and for understanding what formulation features were considered novel.
FAQs
-
Is US 4,065,554 a formulation patent or a method-of-treatment patent?
It is primarily composition/formulation-focused, with claims structured around what the drug product comprises.
-
What is the main design-around path for competitors?
Change the claim-critical element: the active ingredient or the specific formulation/vehicle features required by the claims.
-
Do dependent claims matter more than independent claims in infringement analysis?
Yes when the accused product matches the independent claim but differs on formulation details; dependent claim limitations often determine whether a product “fully” reads on the narrower embodiments.
-
How does the landscape usually evolve after a composition patent from the 1970s?
Common follow-on filings target improved formulations, manufacturing processes, combinations, and additional indications.
-
Is US 4,065,554 still enforceable today?
Given its 1978 issue date, it is generally not enforceable for new commercial activities, but it remains relevant for historical and patent-family landscape work.
References
- Google Patents. “US4065554A.” Accessed 2026-04-26. https://patents.google.com/patent/US4065554A
- USPTO Patent Full-Text and Image Database (PatFT). “US 4,065,554.” Accessed 2026-04-26. https://patft.uspto.gov/
More… ↓
⤷ Start Trial
|
